CancerEpi_KEP

Cancer research at the Clinical Epidemiology Division, Karolinska Institutet.

[CancerEpi_KEP @CancerepiK]

Check out this new article 📰 on CNS relapse in lymphoma patients published in @JCO_ASCO including contributions from our group and colleagues around the world 🌍

https://t.co/mSkP2O0jFW

[Ingrid Glimelius @glimelius]

CNS relapse in lymphomas still a challenge, high-dose metothrexate not enough #lymsm High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma. Great work ⁦@CancerepiK⁩ ⁦@ESmedby⁩ ⁦@tobyeyre82⁩ https://t.co/rXnOVX6wU8

[Joshua Entrop @entjos]

Over the summer my 2. PhD project on childbearing among #NHL survivors by histological and clinical subtype in Sweden 🇸🇪, Denmark 🇩🇰, and Norway 🇳🇴 was published in @BrJHaem 🗞️. A thread 🧵(1/7)

https://t.co/erGZPGFwHw

[International Journal of Cancer @IntJCanc]

✨NOW ONLINE✨

New Nordic study by @entjos et al. highlights the need for timely fertility preservation for #Hodgkin #Lymphoma survivors, particularly males, in order to alleviate treatment effects on future childbearing

🔓OPEN ACCESS
➡️https://t.co/tS2k4ys4QW

[CancerEpi_KEP @CancerepiK]

Check out our new publication 📰 in @IntJCanc on childbearing among #Hodgkin #lymphoma patients treated with ABVD and BEACOPP! You can find a summary of the main findings in this thread 🧵 by @entjos.

[Joshua Entrop @entjos]

Fresh out of press 🗞️ in @IntJCanc, my first PhD study on childbearing among #Hodgkin #lymphoma survivors treated with BEACOPP and ABVD in Sweden 🇸🇪, Denmark 🇩🇰, and Norway 🇳🇴. A thread 🧵(1/6)

https://t.co/y1OA80kgy0

[CancerEpi_KEP @CancerepiK]

Thank you to @glimelius, @ESmedby, and the other collaborators from outside our group 👨‍⚕️👩‍💻

[CancerEpi_KEP @CancerepiK]

Check out this recent publication 📄 on risk of testicular cancer among patients with neurodevelopmental and psychiatric disease 📊 involving researchers from our group! Exciting to see that it even got picked up by @TheTelegraph__ yesterday 🗞:

https://t.co/Lt0XbldyuY

[Ingrid Glimelius @glimelius]

Ended up in the Telegraph today about our research about risk for #TesticularCancer in patients with #ADHD or other neurodevelopmental disorders, but I can not read the news article @graham74GC @tobyeyre82 but the original one is in #BrJCancer

[CancerEpi_KEP @CancerepiK]

Thanks to @carolineweibull, @glimelius, @ESmedby, @Annamartling and the other authors for putting together this comprehensive description of CRCBaSe!

The article is openly 🔓 available at https://t.co/ynNvHIaQB2.

#coloncancer #colorectalcancer

[CancerEpi_KEP @CancerepiK]

Are you interested in colorectal cancer research and searching for data sources? 👨‍⚕️👩‍⚕️ If so, check out our recent publication 📰 on CRCBaSe, a Swedish colorectal cancer database 💾 including information on around 77,000 patients diagnosed between 1995 and 2016 in Sweden 🇸🇪.

[CancerEpi_KEP @CancerepiK]

We're proud of @harrysson_sara who earned her #PhD after an outstanding discussion with her opponent @AndyD1036 last Friday 🥳🎩

Sara's thesis on relapses & cardiac complications in #DLBCL is available online and definitely worth checking out 📰: https://t.co/G5Rn014V6O.

[CancerEpi_KEP @CancerepiK]

You can access the full publication for free using the link below. 🧵(4/4)

https://t.co/8D7qjn0PII

[CancerEpi_KEP @CancerepiK]

Check out our new publication 🎉 "Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden" in @Hemasphere_EHA 📰! Thanks to @carolineweibull & @ESmedby who led this project 👩‍🔬! A 🧵(1/4)

[CancerEpi_KEP @CancerepiK]

Our study shows with the help of #multistate models that the strength of the association between POD and survival changes over time both before and after the 24-month time point. These results augment previous findings suggesting #POD24 as a marker of poor survival. 🧵(3/4)

[CancerEpi_KEP @CancerepiK]

@carolineweibull @glimelius @ESmedby @KnutSmeland

[CancerEpi_KEP @CancerepiK]

This is a great summary of our presentation on fertility among NHL survivors at #ASH22 for all those of you who can follow Norwegian 🇳🇴.

Thank you to @HealthTalkNorge 📰 for featuring our study!

#lymsm

[HealthTalk @HealthTalkNorge]

En ny skandinavisk studie er viktig for både pasienter med non-Hodgkin-lymfom og legene deres, ifølge forskerne som vi møtte på American Society of Hematology (ASH) i New Orleans.

https://t.co/MdGGabjlYD

[CancerEpi_KEP @CancerepiK]

@carolineweibull @Dr_Daniel_Molin @RDAnalyticsAB @KSmedby @entjos

[CancerEpi_KEP @CancerepiK]

Great to see this project on treatment-related CVD 💓 and mortality in #HL presented by @JBaech at #ASH22. Joachim visited us from Aalborg University Hospital this spring in one of our many collaboration 🤝 with the Hematology Department in Aalborg 🇩🇰!

https://t.co/Mg99fGiJpT

[Graham Collins @graham74GC]

Reproductive rates in NHL pts by subtype - Entrop
- Nordic database, 2090 pts; 19,00 comparators
- DLBCL: ⬇️ childbirth rate men & women for 1st 3y only (normalises 3-10y)
- high assisted reproductive rate in men with aggressive histologies
Overall very pos message
#ASH22 #lymsm

[CancerEpi_KEP @CancerepiK]

@carolineweibull @ESmedby

[CancerEpi_KEP @CancerepiK]

Our great Tove Wästerlid 🧑‍🏫 presented yesterday her poster on treatment sequences and survival in follicular #lymphoma patients at #ASH22. Check out her abstract 📄 online!

https://t.co/4ed7vPjLVS